Francis Knuettel II - Jun 14, 2024 Form 4 Insider Report for Chromocell Therapeutics Corp (CHRO)

Role
CEO, Pres., CFO Treas & Secty
Signature
/s/ Francis Knuettel II
Stock symbol
CHRO
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 08:01 PM
Previous filing
Feb 23, 2024
Next filing
Jul 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRO Stock Options Award +27.8K +111.11% 52.8K Jun 14, 2024 Common Stock 27.8K $1.30 Camden Capital LLC F1, F2
transaction CHRO Stock Options Award +324K +613.89% 377K Jun 14, 2024 Common Stock 324K $1.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 14, 2024, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $1.30 per share, which were fully vested.
F2 The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
F3 On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.